Summary
Researchers are looking for new ways to treat children with different types of melanoma
(skin cancer), solid tumors, and lymphomas (blood cancers) that are any of these:
- Advanced, which means cancer spread in the body or cannot be removed with surgery
- Relapsed, which means cancer has come back after it had responded to previous
treatment (responded means it stopped growing, gets smaller, or disappeared)
- Refractory, which means cancer did not respond to previous treatment
Pembrolizumab is an immunotherapy, which is a treatment that helps the immune system
fight cancer. Researchers want to learn if different doses of pembrolizumab can cause at
least 1 of the types of cancer to get smaller or go away.
With Amendment 8, enrolment of participants with solid tumours and participants 6 months
to under 12 years old with melanoma were closed. Enrolment of participants 12-18 years
old with melanoma continues. Enrolment of participants who have tumours with specific
traits (microsatellite-instability-high (MSI-H), and tumour-mutational burden-high =10
mutation/Mb (TMB-H)) also continues.